Preview

Russian Journal of Pediatric Hematology and Oncology

Advanced search

Heterogeneity of neuroblastoma stage 4S: a multidisciplinary view

https://doi.org/10.17650/2311-1267-2017-4-1-83-88

Abstract

4S stage is unique and heterogeneous metastatic neuroblastoma - the most common extracranial solid tumor of childhood. Extremely important is the multidisciplinary approach to the management of this group of patients, from diagnosis to the development of a therapeutic plan and scheme of dynamic observation.

About the Authors

T. V. Shamanskaya
Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
Russian Federation
1 Samory Mashela St., Moscow, 117997


D. Yu. Kachanov
Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
Russian Federation
1 Samory Mashela St., Moscow, 117997


E. V. Feoktistova
Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
Russian Federation
1 Samory Mashela St., Moscow, 117997


G. V. Tereshchenko
Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
Russian Federation
1 Samory Mashela St., Moscow, 117997


Yu. N. Likar
Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
Russian Federation
1 Samory Mashela St., Moscow, 117997


G. M. Muftakhova
Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
Russian Federation
1 Samory Mashela St., Moscow, 117997


S. R. Talypov
Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
Russian Federation
1 Samory Mashela St., Moscow, 117997


S. R. Varfolomeeva
Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
Russian Federation
1 Samory Mashela St., Moscow, 117997


References

1. Cheung N.K., Dyer M.A. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer 2013;13(6):397–411.

2. Berthold F., Simon T. Clinical presentation. In: Neuroblastoma. Cheung N.-K., Cohn S., eds. Springer-Verlag, Berlin, Heidelberg, 2005. Pp. 63–86.

3. Brodeur G.M., Pritchard J., Berthold F. et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11(8):1466–77.

4. Nour-Eldin N.E., Abdelmonem O., Tawfik A.M. et al. Pediatric primary and metastatic neuroblastoma: MRI findings: pictorial review. Magn Reson Imaging 2012;30(7):893–906.

5. Качанов Д.Ю., Шаманская Т.В., Муфтахова Г.М., Варфоломеева С.Р. Нейробластома 4S стадии. Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2014;13(2):9–19. [Kachanov D.Yu., Shamanskaya T.V., Muftakhova G.M., Varfolomeeva S.R. Stage 4S neuroblastoma. Voprosy gematologii/onkologii i immunopatologii v pediatrii = Pediatric Hematology/ Oncology and Immunopathology 2014;13(2):9–19. (In Russ.)].

6. Pagès P.M., Dufour C., Fasola S. et al. Bilateral adrenal neuroblastoma. Pediatr Blood Cancer 2009;52(2):196–202.

7. Katzenstein H.M., Bowman L.C., Brodeur G.M. et al. Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience--a pediatric oncology group study. J Clin Oncol 1998;16(6):2007–17.

8. Schleiermacher G., Michon J., Ribeiro A., et al. Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/ disseminated neuroblastoma (a SIOPEN collaborative study). Br J Cancer 2011;105(12):1940–8.

9. Massaron S., Seregni E., Luksch R. et al. Neuron-specific enolase evaluation in patients with neuroblastoma. Tumour Biol 1998;19(4):261–8.

10. Balassy C., Navarro O.M., Daneman A. Adrenal masses in children. Radiol Clin North Am 2011;49(4):711–27.

11. Brisse H.J., McCarville M.B., Granata S. et al.; International Neuroblastoma Risk Group Project. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology 2011;261(1):243–57.

12. Rufini V., Shulkin B. The evolution in the use of MIBG in more than 25 years of experimental and clinical applications. Q J Nucl Med Mol Imaging 2008;52(4):341–50.

13. Mueller W.P., Coppenrath E., Pfluger T. Nuclear medicine and multimodality imaging of pediatric neuroblastoma. Pediatr Radiol 2013;43(4):418–27.

14. Guglielmi M., De Bernardi B., Rizzo A. et al. Resection of primary tumor at diagnosis in stage IV-S neuroblastoma: does it affect the clinical course? J Clin Oncol 1996;14(5):1537–44.

15. NB2004 protocol. Berthold F (principal investigator). http://www.kinderkrebsinfo.de/dlja_specialistov/protokoly_gpoh/pohkinderkrebsinfotherapiestudien/nb2004/index_rus.html [cited 2016 March 15].

16. Holsten T., Schuster T., Grabhorn E. et al. Liver transplantation as a potentially lifesaving measure in neuroblastoma stage 4S. Pediatr Hematol Oncol 2017:1–7. [Epub ahead of print].

17. van Noesel M.M., Hählen K., Hakvoort-Cammel F.G., Egeler R.M. Neuroblastoma 4S: a heterogeneous disease with variable risk factors and treatment strategies. Cancer 1997;80(5):834–43.


Review

For citations:


Shamanskaya T.V., Kachanov D.Yu., Feoktistova E.V., Tereshchenko G.V., Likar Yu.N., Muftakhova G.M., Talypov S.R., Varfolomeeva S.R. Heterogeneity of neuroblastoma stage 4S: a multidisciplinary view. Russian Journal of Pediatric Hematology and Oncology. 2017;4(1):83-88. (In Russ.) https://doi.org/10.17650/2311-1267-2017-4-1-83-88

Views: 838


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2311-1267 (Print)
ISSN 2413-5496 (Online)
X